These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
262 related items for PubMed ID: 12812701
1. [Thiopurine methyltransferase activity and myelosuppression in inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine]. Gisbert JP, Luna M, Maté J, González-Guijarro L, Cara C, Pajares JM. Med Clin (Barc); 2003 Jun 07; 121(1):1-5. PubMed ID: 12812701 [Abstract] [Full Text] [Related]
2. [Thiopurine methyltransferase activity in inflammatory bowel disease. A study on 7046 Spanish patients]. Gisbert JP, Gomollón F, Cara C, Luna M, González-Lama Y, Pajares JM, Maté J, Guijarro LG. Med Clin (Barc); 2005 Sep 10; 125(8):281-5. PubMed ID: 16159550 [Abstract] [Full Text] [Related]
3. Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study. Gisbert JP, Luna M, Maté J, González-Guijarro L, Cara C, Pajares JM. Hepatogastroenterology; 2006 Sep 10; 53(69):399-404. PubMed ID: 16795981 [Abstract] [Full Text] [Related]
4. [Monitoring of thiopurine methyltransferase and thiopurine metabolites to optimize azathioprine therapy in inflammatory bowel disease]. Gisbert JP, González-Lama Y, Maté J. Gastroenterol Hepatol; 2006 Nov 10; 29(9):568-83. PubMed ID: 17129552 [Abstract] [Full Text] [Related]
10. 5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine. Hande S, Wilson-Rich N, Bousvaros A, Zholudev A, Maurer R, Banks P, Makrauer F, Reddy S, Burakoff R, Friedman S. Inflamm Bowel Dis; 2006 Apr 10; 12(4):251-7. PubMed ID: 16633046 [Abstract] [Full Text] [Related]
11. Thiopurine methyltransferase gene polymorphisms and activity in Chinese patients with inflammatory bowel disease treated with azathioprine. Zhu Q, Cao Q. Chin Med J (Engl); 2012 Oct 10; 125(20):3665-70. PubMed ID: 23075721 [Abstract] [Full Text] [Related]
12. Should thiopurine methyltransferase genotypes and phenotypes be measured before thiopurine therapy in patients with inflammatory bowel disease? Fangbin Z, Xiang G, Minhu C, Liang D, Feng X, Min H, Pinjin H. Ther Drug Monit; 2012 Dec 10; 34(6):695-701. PubMed ID: 23149442 [Abstract] [Full Text] [Related]
13. Differences between children and adults in thiopurine methyltransferase activity and metabolite formation during thiopurine therapy: possible role of concomitant methotrexate. Pettersson B, Almer S, Albertioni F, Söderhäll S, Peterson C. Ther Drug Monit; 2002 Jun 10; 24(3):351-8. PubMed ID: 12021625 [Abstract] [Full Text] [Related]
14. Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease. Gearry RB, Barclay ML, Burt MJ, Collett JA, Chapman BA, Roberts RL, Kennedy MA. Aliment Pharmacol Ther; 2003 Aug 15; 18(4):395-400. PubMed ID: 12940924 [Abstract] [Full Text] [Related]
15. Thiopurine Methyltransferase Genetic Polymorphisms and Activity and Metabolic Products of Azathioprine in Patients with Inflammatory Bowel Disease. Pashazadeh P, Marjani A, Asadi J, Khoshnia M. Endocr Metab Immune Disord Drug Targets; 2019 Aug 15; 19(4):541-547. PubMed ID: 30451123 [Abstract] [Full Text] [Related]
17. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity. Roblin X, Peyrin-Biroulet L, Phelip JM, Nancey S, Flourie B. Am J Gastroenterol; 2008 Dec 15; 103(12):3115-22. PubMed ID: 19086961 [Abstract] [Full Text] [Related]
18. Influences of thiopurine methyltransferase genotype and activity on thiopurine-induced leukopenia in Korean patients with inflammatory bowel disease: a retrospective cohort study. Kim JH, Cheon JH, Hong SS, Eun CS, Byeon JS, Hong SY, Kim BY, Kwon SH, Kim SW, Han DS, Yang SK, Kim WH. J Clin Gastroenterol; 2010 Dec 15; 44(10):e242-8. PubMed ID: 20308917 [Abstract] [Full Text] [Related]
19. Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. Ansari A, Elliott T, Baburajan B, Mayhead P, O'Donohue J, Chocair P, Sanderson J, Duley J. Aliment Pharmacol Ther; 2008 Sep 15; 28(6):734-41. PubMed ID: 19145729 [Abstract] [Full Text] [Related]
20. The impact of thiopurine-S-methyltransferase genotype on the adverse drug reactions to azathioprine in patients with inflammatory bowel diseases. Hlavaty T, Batovsky M, Balakova D, Pav I, Celec P, Gregus M, Zakuciova M, Hlista M, Horakova M, Desatova B, Koller T, Toth J, Kadasi L, Huorka M, Slovak IBD study group (SK IBD). Bratisl Lek Listy; 2013 Sep 15; 114(4):199-205. PubMed ID: 23514552 [Abstract] [Full Text] [Related] Page: [Next] [New Search]